Andra AP fonden Takes $10.06 Million Position in Cencora, Inc. $COR

Andra AP fonden acquired a new stake in Cencora, Inc. (NYSE:COR) during the third quarter, according to its most recent filing with the SEC. The firm acquired 32,200 shares of the company’s stock, valued at approximately $10,063,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. IAG Wealth Partners LLC acquired a new position in Cencora during the 3rd quarter worth approximately $30,000. Integrated Advisors Network LLC grew its stake in shares of Cencora by 26.1% during the 3rd quarter. Integrated Advisors Network LLC now owns 960 shares of the company’s stock worth $300,000 after purchasing an additional 199 shares during the period. DNB Asset Management AS increased its holdings in shares of Cencora by 2.8% in the 3rd quarter. DNB Asset Management AS now owns 35,306 shares of the company’s stock valued at $11,034,000 after purchasing an additional 972 shares in the last quarter. West Family Investments Inc. lifted its stake in shares of Cencora by 8.2% in the third quarter. West Family Investments Inc. now owns 4,065 shares of the company’s stock valued at $1,270,000 after purchasing an additional 307 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Cencora by 12.1% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 380,804 shares of the company’s stock valued at $119,013,000 after buying an additional 40,985 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Up 1.4%

Shares of NYSE COR opened at $371.86 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. Cencora, Inc. has a 12-month low of $248.59 and a 12-month high of $377.54. The company has a market cap of $72.34 billion, a P/E ratio of 44.69, a P/E/G ratio of 1.71 and a beta of 0.68. The stock has a fifty day moving average price of $351.72 and a 200 day moving average price of $333.58.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same period in the previous year, the company posted $3.73 EPS. Cencora’s revenue for the quarter was up 5.5% on a year-over-year basis. Research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s payout ratio is presently 28.85%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Evercore dropped their target price on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. JPMorgan Chase & Co. raised their target price on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. UBS Group raised their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Finally, Bank of America decreased their price target on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $399.00.

Insider Buying and Selling

In other news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 15,220 shares of company stock worth $5,282,867. 0.38% of the stock is currently owned by corporate insiders.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.